We Offer Worldwide Shipping
Login Wishlist

Pinosylvin monomethyl ether

$762

  • Brand : BIOFRON

  • Catalogue Number : BD-P0482

  • Specification : 98.0%(HPLC)

  • CAS number : 35302-70-6

  • Formula : C15H14O2

  • Molecular Weight : 226.3

  • PUBCHEM ID : 5281719

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0482

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

226.3

Appearance

Powder

Botanical Source

Structure Type

Phenols

Category

Standards;Natural Pytochemical;API

SMILES

COC1=CC(=CC(=C1)O)C=CC2=CC=CC=C2

Synonyms

(E)-3-Hydroxy-5-methoxystilbene,(E)-3-Methoxy-5-(2-phenylethenyl)phenol,5-Methoxy-3-stilbenol/3-Methoxy-5-[(E)-2-phenylvinyl]phenol/3-Stilbenol, 5-methoxy-/Phenol, 3-methoxy-5- (2-phenylethenyl)-/O-Methyl-pinosylvin/pinosylvin monomethyl ether/3-methoxy-5-[(E)-2-phenylethenyl]phenol/pinosylvin-O-methyl ether/5-Hydroxy-3-methoxy-trans-stilben/5-Methoxy-3-stilbenol/Phenol, 3-methoxy-5-[(E)-2-phenylethenyl]-/3-hydroxy-5-methoxystilbene

IUPAC Name

3-methoxy-5-[(E)-2-phenylethenyl]phenol

Applications

Density

1.2±0.1 g/cm3

Solubility

Methanol; Chloroform

Flash Point

245.6±7.8 °C

Boiling Point

405.8±24.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C15H14O2/c1-17-15-10-13(9-14(16)11-15)8-7-12-5-3-2-4-6-12/h2-11,16H,1H3/b8-7+

InChl Key

JVIXPWIEOVZVJC-BQYQJAHWSA-N

WGK Germany

RID/ADR

HS Code Reference

2909500000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:35302-70-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

27167107

Abstract

Gallbladder cancer (GBC) is an aggressive malignancy. Although surgical resection may be curable, most patients are diagnosed at an advanced unresectable disease stage. Cholelithiasis is the major risk factor; however the pathogenesis of the disease, from gallstone cholecystitis to cancer, is still not understood. To understand the molecular genetic underpinnings of this cancer and explore novel therapeutic targets for GBC, we examined the key genes and pathways involved in GBC using RNA sequencing. We performed gene expression analysis of 32 cases of surgically-resected GBC along with normal gallbladder tissue controls. We observed that 519 genes were differentially expressed between GBC and normal GB mucosal controls. The liver X receptor (LXR)/retinoid X receptor (RXR) and farnesoid X receptor (FXR) /RXR pathways were the top canonical pathways involved in GBC. Key genes in these pathways, including SERPINB3 and KLK1, were overexpressed in GBC, especially in female GBC patients. Additionally, ApoA1 gene expression suppressed in GBC as compared with normal control tissues. LXR and FXR genes, known to be important in lipid metabolism also function as tumor suppressors and their down regulation appears to be critical for GBC pathogenesis. LXR agonists may have therapeutic value and as potential therapeutic targets.

KEYWORDS

RNA sequence, gallbladder cancer, liver X receptor, lipid metabolism pathways

Title

RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer

Author

Mingxin Zuo,1 Asif Rashid,2 Ying Wang,3 Apurva Jain,1 Donghui Li,1 Anu Behari,4 Vinay Kumar Kapoor,4 Eugene J. Koay,5 Ping Chang,1 Jean Nicholas Vauthey,6 Yanan Li,1 Jaime A. Espinoza,7 Juan Carlos Roa,8 and Milind Javle1

Publish date

2016 Jun 7

PMID

16723552

Abstract

The ability of Mycoplasma hyopneumoniae to persist despite fluoroquinolone treatments was investigated with pigs. Groups of specific-pathogen-free pigs were experimentally infected with M. hyopneumoniae strain 116 and treated with marbofloxacin at the therapeutic dose (TD) or half of the therapeutic dose (TD/2) for 3 days. Results showed that, despite tissue penetration of marbofloxacin, particularly in the trachea and the tracheal secretions, the treatments did not have any influence on M. hyopneumoniae recovery from tracheal swabs. Mycoplasmas were also isolated from inner organs and tissues such as liver, spleen, kidneys, and bronchial lymph nodes. Recontamination of pigs via environment could not explain mycoplasma persistence after medication, as decontamination of pigs and allocation to a new disinfected environment did not have any significant effect on the phenomenon. A significant decrease in the susceptibility level to marbofloxacin of 12 mycoplasma clones reisolated after the treatments (TD/2 and TD) was observed. Two point mutations were found in the ParC quinolone resistance-determining region (QRDR) of DNA topoisomerase IV (Ser80→Phe and Asp84→Asn), and one point mutation was observed just behind the QRDR of ParC (Ala116→Glu). This is the first time that mutations in a gene coding for topoisomerase IV have been described for M. hyopneumoniae after in vivo marbofloxacin treatments in experimentally infected pigs. However, development of resistance is not sufficient to explain M. hyopneumoniae persistence in vivo since (i) marbofloxacin concentrations were above the marbofloxacin MIC of the wild-type strain and (ii) mycoplasmas reisolated after a single injection of marbofloxacin did not display an increased marbofloxacin MIC.

Title

Persistence of Mycoplasma hyopneumoniae in Experimentally Infected Pigs after Marbofloxacin Treatment and Detection of Mutations in the parC Gene

Author

J. Le Carrou,1 M. Laurentie,2 M. Kobisch,1 and A. V. Gautier-Bouchardon1,*

Publish date

2006 Jun;

PMID

24002102

Abstract

Pinnatoxin G (PnTX-G) is a marine toxin belonging to the class of cyclic imines and produced by the dinoflagellate Vulcanodinium rugosum. In spite of its strong toxicity to mice, leading to the classification of pinnatoxins into the class of “fast-acting toxins”, its hazard for human health has never been demonstrated. In this study, crude extracts of V. rugosum exhibited significant cytotoxicity against Neuro2A and KB cells. IC50 values of 0.38 µg mL−1 and 0.19 µg mL−1 were estimated on Neuro2A cells after only 24 h of incubation and on KB cells after 72 h of incubation, respectively. In the case of Caco-2 cells 48 h after exposure, the crude extract of V. rugosum induced cell cycle arrest accompanied by a dramatic increase in double strand DNA breaks, although only 40% cytotoxicity was observed at the highest concentration tested (5 µg mL−1). However, PnTX-G was not a potent cytotoxic compound as no reduction of the cell viability was observed on the different cell lines. Moreover, no effects on the cell cycle or DNA damage were observed following treatment of undifferentiated Caco-2 cells with PnTX-G. The crude extract of V. rugosum was thus partially purified using liquid-liquid partitioning and SPE clean-up. In vitro assays revealed strong activity of some fractions containing no PnTX-G. The crude extract and the most potent fraction were evaluated using full scan and tandem high resolution mass spectrometry. The dereplication revealed the presence of a major compound that could be putatively annotated as nakijiquinone A, N-carboxy-methyl-smenospongine or stachybotrin A, using the MarinLit™ database. Further investigations will be necessary to confirm the identity of the compounds responsible for the cytotoxicity and genotoxicity of the extracts of V. rugosum.

KEYWORDS

dereplication, cyclic imine, HRMS, bioactivity, pinnatoxins

Title

Cytotoxicity, Fractionation and Dereplication of Extracts of the Dinoflagellate Vulcanodinium rugosum, a Producer of Pinnatoxin G

Author

Marie Geiger,1,2,† Gwenaëlle Desanglois,3,† Kevin Hogeveen,3 Valerie Fessard,3 Thomas Leprêtre,1,2 Florence Mondeguer,1 Yann Guitton,1,2 Fabienne Herve,1 Veronique Sechet,1 Olivier Grovel,2 Yves-Francois Pouchus,2 and Philipp Hess1,*

Publish date

2013 Sep;